Asset Details
Do you wish to reserve the book?
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
Do you wish to request the book?
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database
2012
Overview
Objectives Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism,BMJ Publishing Group,Elsevier Limited
Subject
Antibodies, Antinuclear - blood
/ Biological and medical sciences
/ Calcium Channel Blockers - therapeutic use
/ Cyclophosphamide - therapeutic use
/ Diseases of the osteoarticular system
/ Europe
/ Female
/ Glucocorticoids - therapeutic use
/ Humans
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Proton Pump Inhibitors - therapeutic use
/ Raynaud Disease - complications
/ Scleroderma, Diffuse - diagnosis
/ Scleroderma, Diffuse - drug therapy
/ Scleroderma, Diffuse - physiopathology
/ Scleroderma, Limited - diagnosis
/ Scleroderma, Limited - drug therapy
/ Scleroderma, Limited - physiopathology
/ Skin
/ Ulcers
